Myxedema coma represents the most severe manifestation of hypothyroidism, a life-threatening condition where the body’s adaptive mechanisms to prolonged thyroid hormone deficiency falter. Often, the term “coma” is a misnomer, as many patients present with severe decompensated hypothyroidism rather than true unconsciousness. Recognizing the subtle signs and understanding the diagnostic criteria are crucial for timely intervention and improved patient outcomes.
Understanding Myxedema Coma Pathophysiology
The pathophysiology of myxedema coma is rooted in the body’s response to chronic, severe hypothyroidism. The body attempts to maintain homeostasis through various neurovascular adaptations. These include persistent peripheral vasoconstriction, diastolic hypertension, and reduced blood volume – all aimed at preserving core body temperature and vital organ function. However, this delicate balance can be disrupted by precipitating factors, leading to decompensation. Events that further reduce blood volume (like gastrointestinal bleeding or diuretic use), compromise respiration (such as pulmonary infections), or impair central nervous system regulation (stroke, sedatives, hyponatremia) can overwhelm these adaptive mechanisms, pushing a severely hypothyroid patient into myxedema coma.
Key Diagnostic Criteria for Myxedema Coma
Diagnosing myxedema coma requires careful assessment of clinical presentation and consideration of precipitating factors. The classic triad encompasses:
Altered Mental Status
Changes in mental status are a hallmark of myxedema coma. Patients typically exhibit a gradual decline in cognitive function, often evolving over months. Initially, this may manifest as somnolence and lethargy, progressing through stupor and potentially culminating in a comatose state. It’s important to note that fluctuating levels of consciousness may precede a more sustained and profound alteration. Recognizing this progressive decline is crucial for early diagnosis.
Defective Thermoregulation: Hypothermia
Hypothermia, or abnormally low body temperature, is another critical diagnostic feature. In myxedema coma, the severity of hypothermia is often directly correlated with poorer prognosis. Accurate temperature measurement is essential, as standard automatic thermometers may not register temperatures in the hypothermic range. The absence of fever, even in the presence of infection, is a notable characteristic. Exposure to cold environments can exacerbate hypothermia, and the incidence of myxedema coma is notably higher during winter months.
Precipitating Events
Identifying a precipitating event is vital in the diagnostic process. These events act as triggers that destabilize the already compromised physiology of a severely hypothyroid individual. Common precipitating factors include:
- Cold Exposure: Environmental cold stress can overwhelm thermoregulatory mechanisms.
- Infection: Infections, even without fever, can significantly stress the body.
- Medications: Certain drugs like diuretics, tranquilizers, sedatives, and analgesics can further depress CNS function or fluid balance.
- Trauma: Physical injury adds physiological stress.
- Stroke: Cerebrovascular events can impair CNS regulation.
- Heart Failure: Cardiovascular compromise worsens overall decompensation.
- Gastrointestinal Bleeding: Blood loss further reduces already diminished blood volume.
The typical patient profile often involves an elderly woman presenting during winter with altered consciousness and a history of hypothyroidism, thyroid surgery, or radioactive iodine treatment. The absence of previously noted mild diastolic hypertension in a known hypothyroid patient should also raise suspicion for impending myxedema coma.
Physical Examination Findings
Beyond the core diagnostic triad, physical examination may reveal several supportive signs:
- Hypothermia: As previously mentioned, often profound.
- Hypoventilation: Shallow and slow breathing.
- Hypotension: Low blood pressure.
- Bradycardia: Slow heart rate.
- Dry, Coarse Skin: A characteristic feature of hypothyroidism.
- Macroglossia: Enlarged tongue.
- Delayed Deep-Tendon Reflexes: Slowed relaxation phase of reflexes.
Laboratory Diagnosis of Myxedema Coma
Laboratory investigations play a crucial role in confirming the diagnosis and guiding management. Typical findings may include:
- Anemia: Reduced red blood cell count.
- Hyponatremia: Low serum sodium levels.
- Hypoglycemia: Low blood glucose levels.
- Hypercholesterolemia: Elevated cholesterol levels.
- Elevated Serum Creatine Kinase (CK): Indicative of muscle damage, often seen in hypothyroidism.
- Abnormal Thyroid Hormone Levels: In most cases, low serum free thyroxine (FT4) and elevated thyroid-stimulating hormone (TSH) are present, confirming primary hypothyroidism. However, in cases of central hypothyroidism or nonthyroidal illness syndrome, TSH may be inappropriately low or normal despite low FT4.
Differential Diagnosis
It’s important to differentiate myxedema coma from other conditions that can present with altered mental status and hypothermia, such as:
- Sepsis: Although often associated with fever, elderly patients or those with impaired immune systems may present with hypothermia.
- Hypoglycemia: Can mimic altered mental status; blood glucose should be checked immediately.
- Stroke: Can cause sudden neurological changes.
- Drug Overdose: Sedatives, opioids, and other CNS depressants.
- Adrenal Insufficiency: Can present with hypotension and altered mental status.
Myxedema Coma Treatment and Management
Myxedema coma is a medical emergency requiring immediate and aggressive management. Prompt treatment with thyroid hormones and comprehensive supportive care are essential for improving patient outcomes. Despite aggressive treatment, mortality remains significant, ranging from 20% to 50%.
The cornerstone of treatment involves:
-
Thyroid Hormone Replacement: Rapid intravenous administration of thyroid hormones is critical. A large initial loading dose of levothyroxine (T4) is typically given, often followed by liothyronine (T3) if there is no rapid response. Dosage and specific protocols vary, and clinicians must balance the need for rapid thyroid hormone repletion with the risk of cardiac complications.
-
Hydrocortisone Administration: Given the potential for coexisting adrenal insufficiency, intravenous hydrocortisone is routinely administered.
-
Respiratory Support: Hypoventilation is common, and intubation and mechanical ventilation may be necessary.
-
Management of Hypothermia: Passive rewarming with blankets is recommended; active external rewarming is generally avoided as it can cause vasodilation and shock.
-
Correction of Hyponatremia: Mild fluid restriction is usually sufficient. In severe symptomatic hyponatremia, hypertonic saline may be cautiously administered.
-
Blood Pressure Support: Cautious fluid resuscitation is the initial step for hypotension. Vasopressors like dopamine may be needed if fluid therapy is insufficient.
-
Glucose Management: Hypoglycemia should be promptly treated with glucose administration.
-
Identification and Treatment of Precipitating Events: A thorough search for and treatment of the underlying trigger (e.g., infection) is crucial. Empirical antibiotics may be warranted while infection is being ruled out.
| MANAGEMENT OF MYXEDEMA COMA |
|---|
| 1.Hypothyroidism |
| 1a |
| 2.Hypocortisolemia |
| 3. Hypoventilation |
| 4. Hypothermia |
| 5. Hyponatremia |
| 6. Hypotension |
| 7. Hypoglycemia |
| 8. Precipitating event |
Conclusion
Myxedema coma is a critical endocrine emergency demanding prompt recognition and aggressive treatment. A high index of suspicion, especially in elderly patients with known or suspected hypothyroidism presenting with altered mental status, hypothermia, and potential precipitating factors, is paramount. Early diagnosis based on clinical criteria and laboratory findings, coupled with immediate initiation of thyroid hormone replacement and supportive measures, offers the best chance of improving outcomes in this life-threatening condition.
References
Chen YJ, Hou SK, How CK, et al. Diagnosis of unrecognized primary overt hypothyroidism in the ED. Am J Emerg Med 2010;28:866-870. http://www.ncbi.nlm.nih.gov/pubmed/ 20887907
Dutta P, Bhansali A, Masoodi SR, et al. Predictors of outcome in myxoedema coma: a study from a tertiary care centre. Crit Care2008;12: R1. http://www.ncbi.nlm.nih.gov/pubmed/18173846
Gwiezdzinska J, Wartofsky L. Thyroid emergencies. Med Clin North Am 2012; 96: 385-403
Jonklaas J, Bianco AC, Bauer AJ, Burman KD, Cappola AR, Celi FS, Cooper DS, Kim BW, Peeters RP, Rosenthal MS, Sawka AM. Guidelines for the treatment of hypothyroidism. Prepared by the American Thyroid Association task force on thyroid hormone replacement. Thyroid 2014; 24: 1670-1751.
Liamis G, Filippatos TD, Liontos A, Elisaf MS. Hypothyroidism-associated hyponatremia: mechanisms, implications and treatment. Eur J Endocrinol 2017; 176: R15-R20.
Ono Y, Ono S, Yasunaga H, Matsui H, Fushimi K, Tanaka Y. Clinical characteristics and outcomes of myxedema coma: analysis of a national inpatient database in Japan. J Epidemiol 2017; 27: 117-122
Reinhardt W, Mann K. Incidence, clinical picture, and treatment of hypothyroid coma: results of a survey. Med Klin1997; 92: 521-524. http://www.ncbi.nlm.nih.gov/pubmed/9411198
Wiersinga WM. Hypothyroidism, inWWW.THYROIDMANAGER.ORG
